Mental disorders are an urgent health crisis worldwide, especially exacerbated by the pandemic in recent years.

SmallCapFirm

Eying Making A Name For Themselves In A Burgeoning Market Worth Billions, This Biotech Idea Needs Full Attention

The Complete Report Arrives 7:00PM EST Tuesday

*SMS Sign-up Details Below*

January 11th

SCF Readers,

Mental disorders are an urgent health crisis worldwide, especially exacerbated by the pandemic in recent years.

As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6Tn by 2030.

With this rise, doctors/scientists/companies are looking for novel new approaches to combat these issues.

One treatment that has been gaining steam in recent years is the use of psych-e-delics.

The psych-e-delic drugs market is expected to grow at a robust rate and reach a value of $6.33Bn in 2026 from $3.21Bn in 2021 as there is a large unmet need for treatment driving this adoption.

In December 2020, the World Health Organization (WHO) stated that 264 million people suffer from depression.

Growing evidence has suggested that psych-e-delic drugs could treat depression effectively. In a study published in The New England Journal of Medicine, researchers conducted a randomized trial on psi-lo-cybin and found that it is almost as good - if not more effective - than the current antidepressants.

At the end of the six-week trial, all but one of the participants reported a marked improvement in their depressive symptoms - a positive development indeed.

North America is predicted to remain the largest region in the psych-e-delic drugs market due to a surge of clinical trials, massive in-vest-ments, regulatory support, and widespread public awareness.

For those reasons, I've been eyeballing small biotech companies who display tremendous upside potential in taking this fast-growing market to task.

At 7:00PM EST today, you'll get the full report on a company that's just so looking to do that.

To give you something to chew on ahead of time, I've compiled a list of 3 potential catalysts that could fuel this profile to a vertical jump near term.

Key Details Now - 3 Potential Breakout Catalysts For Your New Biotech Profile

#1. New listing news and DTC eligibility could draw serious attention to this tiny company flying under Wall Street's radar.

#2. January news. A major announcement was just made by this company that could have game-changing ramifications for this profile in 2022 and beyond.

#3. With fewer than 40Mn shares in its float, the potential for volatility could appear at a moment's notice.

Since you've got a little time now, do this:

image

Your full report arrives soon. Be ready.

Sincerely,

Axel Adams

Editor, SCF


Source


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media.